Polypyrimidine tract binding protein 1 regulates the activation of mouse CD8 T cells.
D'Angeli V. et al, (2022), Eur J Immunol, 52, 1058 - 1068
Screening for Immunodeficiencies in Children With Invasive Pneumococcal Disease: Six-year Experience From a UK Children's Hospital
Bijker EM. et al, (2022), Pediatric Infectious Disease Journal, 41, 575 - 578
Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and with Human Immunodeficiency Virus on Antiretroviral Therapy during the First South African Infection Wave
Snyman J. et al, (2022), Clinical Infectious Diseases, 75, E249 - E256
Systematic review of host genomic biomarkers of invasive bacterial disease: Distinguishing bacterial from non-bacterial causes of acute febrile illness.
Kelly E. et al, (2022), EBioMedicine, 81
Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials
Billard MN. et al, (2022), Journal of Clinical Epidemiology, 147, 11 - 20
Monogenic inflammatory bowel disease-genetic variants, functional mechanisms and personalised medicine in clinical practice.
Azabdaftari A. et al, (2022), Hum Genet
Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
Serra EG. et al, (2022), Nat Commun, 13
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Strauss KA. et al, (2022), Nature medicine
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Strauss KA. et al, (2022), Nature medicine
Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus.
Sheerin D. et al, (2022), Cell Biosci, 12
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Control of backbone chemistry and chirality boost oligonucleotide splice switching activity.
Kandasamy P. et al, (2022), Nucleic Acids Res, 50, 5443 - 5466
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Tuekprakhon A. et al, (2022), Cell
Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening.
Dangouloff T. et al, (2022), Dev Med Child Neurol
The female protective effect against autism spectrum disorder
Wigdor EM. et al, (2022), Cell Genomics, 2